<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046379</url>
  </required_header>
  <id_info>
    <org_study_id>Lipidomics in Fabry</org_study_id>
    <nct_id>NCT05046379</nct_id>
  </id_info>
  <brief_title>Studying Lipids as Potential Biomarkers in Patients With Fabry Disease</brief_title>
  <official_title>Lipidomics for Identification of New Biomarkers for Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare levels of lipids between well characterised enzymatically-genetically-phenotypically&#xD;
      patients with Fabry disease and healthy controls (with no Fabry disease).&#xD;
&#xD;
      Correlate levels of lipids in patients with Fabry disease to clinical outcomes/manifestations&#xD;
      of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that Sphingosine-1 Phosphate (S1P) or any other related sphingoid bases&#xD;
      and/or other lipid class could be a marker of the severity of cardiovascular remodelling in&#xD;
      Fabry disease.&#xD;
&#xD;
      The overall approach is, by minimising possible pre-analytical and analytical biases, to&#xD;
      study by lipidomics in well characterised enzymatically, genetically and phenotypically&#xD;
      patients with Fabry disease, if S1P or any other lipid (including other glycosphingolipids)&#xD;
      is shown to be a biomarker for the diagnosis, monitoring of disease activity and prognosis&#xD;
      (including cardiovascular outcomes).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lipidomics</measure>
    <time_frame>Samples are going be collected during 1 year at the fasting state in the morning. At a random day in both Fabry patients with no treatment and cases. Up to 24 hours before next treatment in Fabry patients with ongoing treatment.</time_frame>
    <description>Lipid species from several lipid classes</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Fabry disease</arm_group_label>
    <description>Adult men and women with well characterized Fabry disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls (with no Fabry disease)</arm_group_label>
    <description>Adult men and women from the endocrinology and nephrology in- or out-patient clinic</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biobank Väst&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult men and women with well characterized Fabry disease and adult men and women with no&#xD;
        Fabry disease and liver disease with elevated transaminases and ongoing infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for cases:&#xD;
&#xD;
          -  Adult men and women&#xD;
&#xD;
          -  Well characterized Fabry disease in terms of i. alpha-Gal A enzyme activity, ii.&#xD;
             mutation in GLA gene, and iii. disease manifestations&#xD;
&#xD;
          -  Followed at one of the 3 centers for patients with Fabry disease in Sweden (Karolinska&#xD;
             in Stockholm, Sahlgrenska in Gothenburg, Akademiska in Uppsala)&#xD;
&#xD;
        Signed informed consent prior to sample collection is mandatory for inclusion to the study.&#xD;
&#xD;
        Inclusion criteria for controls:&#xD;
&#xD;
          -  Adult men and women&#xD;
&#xD;
          -  Followed/treated at the endocrinology or nephrology in- or out-patient clinic at&#xD;
             Sahlgrenska University Hospital in Gothenburg&#xD;
&#xD;
          -  Matched for age, sex, estimated Glomerular filtration rate (eGFR) with the cases with&#xD;
             Fabry disease&#xD;
&#xD;
        Exclusion criteria for controls:&#xD;
&#xD;
          -  Fabry disease&#xD;
&#xD;
          -  Liver disease with elevated transaminases&#xD;
&#xD;
          -  Ongoing infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Blomqvist, Ass.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Västra Götalandsregion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Fabry disease</keyword>
  <keyword>Lipidomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

